Breaking News on Drug Discovery |
News headlines > Emerging targets
Pfizer's GORD therapy enters the clinic
06-Aug-2007 - Pfizer has initiated a Phase I study for its gastro oesophageal reflux disease (GORD or GERD using the US spelling) therapy that it licensed from Kosan Biosciences, in a deal worth up to $250m (€181m).
How does HIV cause AIDS?
02-Aug-2007 - Remarkably, despite being over 25 years into the HIV/AIDS epidemic, scientists still don't have an answer to the seemingly simple question: how does HIV cause AIDS?
HIV therapy leads way in personalised medicine
02-Aug-2007 - GlaxoSmithKline (GSK) has opened the flood gates into the world of personalised medicine with the world's first ever approved genetic test, which predicts a life threatening side effect of one of its antiretroviral drugs.
Merck bulks up cardiovascular pipeline
02-Aug-2007 - Merck & Co. is to bolster its late-stage cardiovascular pipeline through the acquisition of US-based pharma company NovaCardia.
Drugs moving into the clinic: 23
01-Aug-2007 - The latest in a series of periodic roundups of drugs that have moved from preclinical research into clinical testing via the announcement of a Phase I trial or an application for a trial to industry regulators.
Novogen's arthritis drug edges towards human trials
31-Jul-2007 - The latest preclinical experiments by Novogen on its new class of arthritis drugs have encouraged the Australian biotech company in its quest to test the new treatment concept in clinical trials.
Medivation drug sets its sights on Huntington's disease
31-Jul-2007 - Having already shown promising results in Alzheimer's patients, Medivation's drug that protects brain cells is now entering mid-stage clinical trials for Huntington's disease.
Drugs moving into the clinic: 22
30-Jul-2007 - The latest in a series of periodic roundups of drugs that have moved from preclinical research into clinical testing via the announcement of a Phase I trial or an application for a trial to industry regulators.
GlaxoSmithKline inks $1.5bn deal with Targacept
30-Jul-2007 - GlaxoSmithKline (GSK) has forged a $1.5bn (€1.1bn) alliance with US biopharma company Targacept, to develop drugs aimed at central nervous system (CNS) related disorders.
Panacos develops new class of fusion inhibitors
26-Jul-2007 - Panacos, a US based pharma firm, has outlined its work to identify three new series of compounds that inhibit HIV fusion at a different site to the only approved fusion inhibitor, Roche's Fuzeon (enfuvirtide).
Benitec's three-pronged RNA attack on HIV
25-Jul-2007 - Australian biotech company, Benitec, is about to start dosing patients in the first ever human trial of its RNA therapy, which attacks HIV on three separate fronts.
Innovative drugs highlighted at AIDS expo
24-Jul-2007 - As scientists continually strive to develop new ways to tackle the HIV/AIDS pandemic, several new drugs and their targets were highlighted at the ongoing International Aids Society (IAS) Conference.
MedImmune's antibody gives hope to asthma sufferers
24-Jul-2007 - MedImmune has announced that interim Phase I results for its new monoclonal antibody (MAb) suggest that it is well tolerated and shows biological activity in adults with asthma.
MHRA stalls cannabis-based MS drug
23-Jul-2007 - A UK firm developing cannabis-derived multiple sclerosis (MS) treatments has decided to pull an EU application for its lead candidate Sativex, following demands by UK regulators for additional data in support of the treatment.
Schering-Plough bolsters late-stage cardiac pipeline
23-Jul-2007 - Schering-Plough has licensed acadesine (AICA-riboside), a potential first-in-class drug for the prevention of ischemia-reperfusion injury from PeriCor Therapeutics to bolster its cardiac therapeutics pipeline.
Enzyme structure may breathe new life into asthma R&D
19-Jul-2007 - Swedish researchers have solved the crystal structure of the enzyme that plays a pivotal role in the asthma biocascade, providing information that could lead to more efficient asthma therapies.
Acambis' universal vaccine enters the clinic
18-Jul-2007 - UK firm Acambis has announced that its universal influenza vaccine candidate has entered Phase I trials, hoping to prove a key weapon in the fight against pandemic flu and last-minute production panics.
Fresenius antibody for cancer complication nearing debut?
18-Jul-2007 - A novel approach to treating malignant ascites, a serious complication affecting many different types of cancer, could be on the market as early as next year after showing a positive effect on progression and survival in a Phase II/III clinical trial.
ITS a 'winner' for mutating virus vaccine funding
16-Jul-2007 - Immune Targeting Systems (ITS) has received £4m (€5.9m) to aid in its development of synthetic peptide vaccines for mutating viruses such as influenza, HIV and Hepatitis C.
MediGene's modified virus kills tumours
11-Jul-2007 - MediGene has revealed clinical results for its modified herpes virus that can selectively kill cancer tumours, while leaving healthy cells intact.
Anticalins look promising
10-Jul-2007 - A new generation of therapeutic protein products has entered the biopharma scene and are proving more efficient than antibodies when using the same drug delivery systems.
Xenical spin-offs could slim down tumours
10-Jul-2007 - Roche's obesity drug Xenical could be the inspiration for a new class of drugs to treat cancer, if preliminary experimental results involving cancer cells are backed up by further studies.
New drug target could prevent kidney transplants
10-Jul-2007 - Researchers have discovered a genetic defect that causes a serious kidney disease, thus opening the door to new therapies that could avoid the need for a transplant.
Multi-faceted drug adds arthritis string to its bow
09-Jul-2007 - A UK biopharma firm's lead drug candidate has now shown good preclinical results for rheumatoid arthritis, adding to its clinical efficacy in Alzheimer's.
Colgate-Palmolive elects new CEO
05-Jul-2007 - Global oral and personal care player Colgate-Palmolive has announced that Ian Cook has taken over from Reuben Mark as CEO of the company as part of a long-term succession plan that will allow the out-going Mark to retire.
© 2000/2009 - Decision News Media SAS - All right reserved.
